| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
LONDON & ZURICH, Switzerland—Late in 2016, Heptares Therapeutics, a wholly owned subsidiary of Sosei Group Corp., signed a share purchase agreement to acquire 100 percent of G7 Therapeutics, a privately held drug discovery and development company based in Switzerland, for 12 million Swiss francs in cash (about $11.75 million).
 
The strategic acquisition broadens and strengthens Heptares’ intellectual property and platform for structure-based drug design and development focused on G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases.
 
The combination of Heptares’ and G7 Therapeutics’ platforms is anticipated to increase Heptares’ R&D productivity in terms of generating stabilized GPCRs and high-quality GPCR structures that underpin discovery efforts for its proprietary pipeline and for partners.
 
G7 Therapeutics has developed proprietary approaches for stabilizing GPCRs (called SaBRE and CHESS), which are different and highly complementary to the StaR platform developed by Heptares. SaBRE and CHESS are of particular use where the target GPCR is present in very low numbers on cells and the methods are particularly powerful in the numbers of stabilizing mutations that can be identified in a short time for rapidly generating high-quality GPCRs.
 
Upon completion of the acquisition in November, G7 Therapeutics became a wholly owned Zurich-based subsidiary of Heptares and plans called for renaming the company Heptares Zurich. The subsidiary will be led by Fiona Marshall, chief scientific officer at Heptares and at Sosei.
 
“We are delighted to complete the acquisition G7 Therapeutics,” said Marshall. “We believe that the platform G7 has developed is truly complementary to our StaR platform and will expand our capacity to explore more of the ‘GPCRome’ to deliver novel candidates against targeted GPCRs for both our proprietary pipeline and for partnered programs.”
 
Carlo Bertozzi, CEO of G7 Therapeutics, added: “Heptares has an impressive track record of technology development resulting in a world-leading platform that has generated multiple product opportunities targeting many GPCR targets across diverse disease areas. We are excited to combine our platforms and capabilities through this transaction and to further advance GPCR-targeted drug discovery, an area of significant untapped potential.”
 
“Approximately 30 percent of approved medicines in pharmaceutical company portfolios today act by modulating GPCR activity, making GPCRs one of if not the most important target families for drug discovery and a major pillar upon which the global industry has been built,” concluded Peter Bains, CEO of Sosei. “Heptares has already established a world-leading position in this area, building a diverse pipeline of proprietary candidates as well as attracting major pharma company partners. This acquisition is a further step towards delivering Sosei’s strategy by consolidating and extending this leadership position, and expanding our capacity to generate a sustainable pipeline of new drug candidates for development ourselves in select disease areas, and for our partners.”

Related Topics

Published In

Volume 13 - Issue 1 | January 2017

January 2017

January 2017 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue